All relevant data are within the paper and its Supporting Information files. Somatic *CCND1* mutation data and clinico-pathological characteristics for the 29,432 patients analyzed from the original 124 publications in this study are also freely available and can be found on the cBioPortal via the following specific link: <http://bit.ly/2BjBlBs>. Similarly, *CCND1* gene amplification data for the 28,769 patients analyzed from the original 124 publications are also freely available and can be found via the following cBioPortal link: <http://bit.ly/2AJ1eJW>.

Introduction {#sec001}
============

Cyclin D1, encoded by the *CCND1* gene, is a core cell cycle regulator that promotes cellular proliferation and is frequently overexpressed in human cancers. Alterations of cyclin D1 resulting in nuclear protein expression is thought to promote tumorigenesis in various types of cancers\[[@pone.0199688.ref001]\]\[[@pone.0199688.ref002]\], often as a result of *CCND1* gene amplification, such as in breast, lung, bladder carcinomas \[[@pone.0199688.ref003]\]\[[@pone.0199688.ref004]\], or as a result of *CCND1* translocation in mantle cell lymphoma \[[@pone.0199688.ref005]\]. Accumulating evidence also suggests that mutations of the *CCND1* gene that result in nuclear retention and constitutive activation of CDK4/6 kinases are oncogenic drivers in cancer \[[@pone.0199688.ref006]\]\[[@pone.0199688.ref007]\]\[[@pone.0199688.ref008]\]\[[@pone.0199688.ref009]\]. Oncogenic mutations of *CCND1* have been previously reported in endometrial and esophageal carcinomas \[[@pone.0199688.ref010]\]\[[@pone.0199688.ref011]\]\[[@pone.0199688.ref012]\], however, the spectrum of *CCND1* mutations across human cancers has not been systematically investigated.

The c-terminus of cyclin D1 contains a nuclear export signal and a phospho-degron, which is a region involved in cyclin D1 phosphorylation, nuclear export, ubiquitination and protein degradation. During the S phase of the cell cycle, phosphorylation of cyclin D1 at Thr-286 by GSK3β triggers cyclin D1 nuclear export and ubitiquin-mediated proteolysis via the 26S proteasome in the cytoplasm \[[@pone.0199688.ref013]\]\[[@pone.0199688.ref014]\]\[[@pone.0199688.ref015]\]. For this reason, mutations in the c-terminus of cyclin D1 may result in oncogenic activation of cyclin D1 via inhibition of Thr-286 phosphorylation, nuclear export and protein degradation, thereby promoting cyclin D1 nuclear accumulation \[[@pone.0199688.ref006]\]. Nuclear retention of cyclin D1 constitutively activates CDK4/6 kinases through the cell cycle and thereby promotes cellular proliferation and tumorigenesis \[[@pone.0199688.ref012]\].

Specific *CCND1* c-terminal mutations involving Thr286 and Pro287 have been previously reported in endometrial cancer, such as T286I, P287T, P287S, which resulted in nuclear accumulation of cyclin D1, gain-of-function and cellular transformation \[[@pone.0199688.ref010]\]\[[@pone.0199688.ref011]\]. Endometrial carcinoma is the most frequently diagnosed type of gynecological malignancy, with \~40,000 new cases and 7,500 mortalities reported in the United States in 2008 \[[@pone.0199688.ref016]\]. Currently, there are no FDA-approved or NCCN-compendium listed treatments specifically for patients with *CCND1*-mutant uterine endometrioid carcinoma. However, there are clinical trials evaluating palbociclib, a CDK4/6 specific inhibitor (codenamed PD-0332991, trade name Ibrance) \[[@pone.0199688.ref002]\]\[[@pone.0199688.ref017]\], including a phase 2 trial in patients with metastatic endometrial cancer (ClinicalTrials.gov Identifier: NCT02730429), underscoring the importance of identifying mechanisms of CDK4 activation in endometrial cancer.

Recently, The Cancer Genome Atlas (TCGA) project and other whole exome studies, such as MSK-IMPACT trial, have molecularly characterized many different types of tumors, including endometrial adenocarcinomas \[[@pone.0199688.ref018]\]\[[@pone.0199688.ref019]\]. The TCGA Data Portal and other publicly available online data mining programs offer a host of tools that can be used to interrogate specific genetic events relative to survival and clinico-pathological characteristics, as well as to generate hypotheses for future testing on a variety of tumor types \[[@pone.0199688.ref020]\]\[[@pone.0199688.ref021]\].

The goal of this study was to mine whole-exome sequencing data from published studies representing a large number of cases and a plethora of cancer diagnoses to determine the frequency and spectrum of activating *CCND1* mutations across human cancers. Here we demonstrate that activating, putative driver *CCND1* mutations were of low frequency across all cancer types, but were predominantly enriched in uterine endometrioid-type adenocarcinoma.

Methods {#sec002}
=======

Study type and design {#sec003}
---------------------

With approval of a BIDMC/DFCI Institutional Review Board, we performed an observational retrospective secondary data analysis of clinically-annotated multi-platform cancer--omics datasets from the Cancer Genome Atlas Project (TCGA) and other previously published cancer genomics datasets. A total of 124 published studies with sequencing data ([S1 Table](#pone.0199688.s001){ref-type="supplementary-material"}), representing 29,432 cases from diverse cancer types and sites of origin, such as carcinoma, melanoma, mesothelioma, germ cell tumor, sarcoma and lymphoma/leukemia, were interrogated for *CCND1* mutations. We exploited public available online tools and resources in order to data mine the cancer datasets with respect to *CCND1* alterations, to interrogate different clinic-pathological characteristics relative to genomic alterations of *CCND1*, and to confirm the effect of specific *CCND1* mutations on its biological and oncogenic function.

Cancer cohorts, gene amplification and gene mutation {#sec004}
----------------------------------------------------

Clinical and molecular data from up to 124 previously published cancer genomics studies ([S1 Table](#pone.0199688.s001){ref-type="supplementary-material"}) was analyzed with respect to *CCND1* amplification and mutations via the cBio Cancer Genomics Portal ([http://cbioportal.org](http://cbioportal.org/); Memorial Sloan Kettering Cancer Center, New York, NY) \[[@pone.0199688.ref020]\]\[[@pone.0199688.ref021]\]. The cohorts were queried for *CCND1* gene amplification or mutations in the cbio portal by using the advanced onco query language (*CCND1*: AMP or *CCND1*: MUT) \[[@pone.0199688.ref020]\]\[[@pone.0199688.ref021]\]. In this manuscript, copy number gain was defined as gain of one gene copy number, while amplification was defined as gain of 2 or more gene copy numbers. Online analysis was performed between January 1^st^, 2015 and May 7th, 2018.

*CCND1* mutations specifically in primary endometrial carcinoma were interrogated via the cbio portal and via the advanced onco query language specifically in the endometrial carcinoma TCGA study with sequencing data (n = 248) \[[@pone.0199688.ref018]\]. In a similar manner, *CCND1* mutations in advanced, metastatic endometrial carcinoma samples were interrogated specifically in the MSK IMPACT clinical cohort of advanced/metastatic endometrial carcinoma cases (n = 210) via the cBio portal \[[@pone.0199688.ref019]\].

In the primary endometrial carcinoma TGCA cohort, the following molecular and histological subsets were also analyzed via the cBio portal and by using the advanced onco query language: 1) complete endometrioid-type tumors (n = 232), 2) copy number high tumors (n = 60), 3) copy number low tumors (n = 90), 4) MSI (hypermutated) tumors (n = 65), 5) POLE (ultramutated) tumors (n = 17), and 6) tumors with specific serous-type histology (n = 53).

Review of pathological data {#sec005}
---------------------------

Pathology reports from the endometrial carcinoma TCGA corhort were downloaded via the cBio portal. Quality control hematoxylin and eosin (H&E) images from frozen and permanent sections from TCGA cohort were re-analyzed by a board-certified gynecologic pathologist (D.L.) to confirm histological subtype via the TCGA Biosig website hosted at Lawrence Berkeley National (<http://tcga.lbl.gov:8080/biosig/tcgadownload.do>), and via the Cancer Digital Slide Archive ([http://cancer.digitalslidearchive.net](http://cancer.digitalslidearchive.net/); Emory University, Atlanta, GA). Tumor stage and overall FIGO grade were also independently re-evaluated whenever possible; however, they were deferred to the available pathology reports since only limited virtual images from each case were publicly available for review. For the MSK IMPACT cohort of advanced, metastatic endometrial cancer, histological subtype was deferred to the reported subtype since H&E images were not publicly available for re-review.

Analysis of *CCND1* mutations {#sec006}
-----------------------------

Somatic *CCND1* mutations derived from exome studies, including from TCGA and MSK IMPACT endometrial carcinoma cohorts, were retrieved via the cBio portal (<http://www.cbioportal.org/public-portal/>). The effect of specific somatic mutations on *CCND1* function was determined by cross-referencing them to previously published reports, wherein the effect of specific *CCND1* mutations on Cyclin D1 activation or gain-of-function was demonstrated either *in vitro* or *in vivo* \[[@pone.0199688.ref006]\]\[[@pone.0199688.ref012]\]\[[@pone.0199688.ref011]\]. In addition, effects of *CCND1* mutations were independently queried in the online Precision Oncology Knowledge Base tool (<http://www.OncoKB.org>), which is a publicly available, evidence-based web resource tool that annotates and curates the biologic and oncogenic effects, as well as the predictive significance of somatic molecular alterations present in patient tumors with the goals of facilitating the interpretation of genomic alterations and supporting optimal treatment decisions \[[@pone.0199688.ref022]\].

Results {#sec007}
=======

Frequency of *CCND1* mutations across cancer {#sec008}
--------------------------------------------

To assess frequency and spectrum of *CCND1* mutations across cancer, molecular data from 124 studies ([S1 Table](#pone.0199688.s001){ref-type="supplementary-material"}), representing 29,432 cases/patients from diverse cancer types and sites of origin, were mined via the cBio Cancer Genomics Portal ([http://cbioportal.org](http://cbioportal.org/)) \[[@pone.0199688.ref020]\]\[[@pone.0199688.ref021]\]. Somatic mutation of the *CCND1* gene was seen in 0.5% (151 of 29,432) of cases spanning all regions of the cyclin D1 protein ([Table 1](#pone.0199688.t001){ref-type="table"} and [Fig 1A](#pone.0199688.g001){ref-type="fig"}). By combining the molecular data of studies from the same cancer subtype and site of origin, the most frequently *CCND1*-mutated cancer subtypes were mantle cell lymphoma (34.5%, 10 of 29 cases), endometrial adenocacinoma (6.5%, 30 of 458 cases), multiple-myeloma (3.3%, 7 of 205 cases), colorectal carcinoma (1.1%, 23 of 2067 cases), melanoma (1.1%, 8 of 708 cases), skin non-melanoma cancer (1.1%, 2 of 177 cases) and uterine sarcoma (1.1%, 1 of 93 cases).

![Diagrams of *CCND1* mutations.\
Across all human cancers analyzed (A), or specifically in the mantle cell lymphoma cohort (B), in the primary endometrial endometrioid adenocarcinoma TCGA cohort (C), and in the advanced or metastatic endometrial carcinoma MSK-IMPACT cohort (D).](pone.0199688.g001){#pone.0199688.g001}

10.1371/journal.pone.0199688.t001

###### Exome studies containing *CCND1* mutations with respective cancer type and *CCND1* mutation frequency.

![](pone.0199688.t001){#pone.0199688.t001g}

  Study   Cancer type (Source, citation)                         *CCND1* mut   Sample size   \% mutated
  ------- ------------------------------------------------------ ------------- ------------- ------------
  1       Mantle Cell Lymphoma (IDIBIPS 2013)                    10            29            34.5%
  2       Melanoma (Broad/Dana Farber, Nature 2012)              2             25            8.0%
  3       Endometrial Carcinoma (TCGA, Nature 2013)              15            248           6.1%
  4       Glioma (MSK, Neuro Oncol 2017)                         1             22            4.5%
  5       Colorectal carcinoma (Genentech, Nature 2012)          3             72            4.2%
  6       Skin sq. cell carcinoma (DFCI, Clin Cancer Res 2015)   1             29            3.4%
  7       Multiple Myeloma (Broad, Cancer Cell 2014)             7             205           3.3%
  8       Stomach Adenocarcinoma (Tokyo, Nat Genet 2014)         1             30            3.3%
  9       NCI-60 Cell Lines (NCI, Cancer Res. 2012)              2             60            3.3%
  10      Skin melanoma UCLA (Cell 2016)                         1             38            2.6%
  11      Colorectal Adenocarcinoma (DFCI 2016)                  15            619           2.4%
  12      Rhabdomyosarcoma (NIH, Cancer Discov 2014)             1             43            2.3%
  13      Skin Cutaneous Melanoma (Broad, Cell 2012)             2             121           1.7%
  14      Low-Grade Gliomas (UCSF, Science 2014)                 1             61            1.6%
  15      Bladder Urothelial Carcinoma (TCGA, Nature 2014)       2             130           1.5%
  16      Lung Squamous Cell Carcinoma (TCGA, Nature 2012)       2             178           1.1%
  17      Lung Adenocarcinoma (TCGA, Nature 2014)                2             230           0.9%
  18      Breast cancer xenog (British Columbia, Nature 2014)    1             116           0.9%
  19      NSCLC (TCGA 2016)                                      9             1144          0.8%
  20      Stomach/Esophageal (TCGA)                              4             518           0.8%
  21      Cancer Cell Line Encyclop (Novartis/Broad, Nat 2012)   7             1020          0.7%
  22      Ampulary carcinoma (BMC, 2016)                         1             160           0.6%
  23      Lung Adenocarcinoma (Broad, Cell 2012)                 1             183           0.5%
  24      MSK-IMPACT various tumor types (Nat Med 2017)          57            10945         0.5%
  25      LGG-GBM (TCGA 2016)                                    3             812           0.4%
  26      H&N Squamous Cell Carcinoma (TCGA, Nature 2015)        1             279           0.4%
  27      Stomach Adenocarcinoma (TCGA, Nature 2014)             1             290           0.3%

The most commonly mutated amino acid of cyclin D1 was Proline 287, followed by Threonine 286, both of which are located in the c-terminus of cyclin D1 ([Fig 1A](#pone.0199688.g001){ref-type="fig"}). The third most common mutated amino acid was Tyrosine 44, which is located in the n-terminus of cyclin D1 ([Fig 1A](#pone.0199688.g001){ref-type="fig"}). The location of *CCND1* mutations appeared to be tissue specific. In mantle cell lymphoma and multiple myeloma, the majority of *CCND*1 mutations occurred within the amino terminal domain of cyclin D1 ([S2 Table](#pone.0199688.s002){ref-type="supplementary-material"} and [Fig 1B](#pone.0199688.g001){ref-type="fig"}), while in endometrial adenocarcinomas, and less frequently in colorectal carcinoma and melanoma, *CCND1* mutations centered on the carboxy terminal domain ([Fig 1C and 1D](#pone.0199688.g001){ref-type="fig"} and [S1 Fig](#pone.0199688.s003){ref-type="supplementary-material"}). These findings support the notion that endometrial adenocarcinomas are enriched for a unique spectrum of somatic *CCND1* alterations, in which a significant number of *CCND1* mutations occur in the c-terminal domain of cyclin D1 compared to other cancer subtypes.

Frequency of *CCND1* amplification in cancer {#sec009}
--------------------------------------------

Somatic *CCND1* mutations occurred less frequently than *CCND1* gene amplification. Overall, in contrast to somatic mutations, *CCND1* gene amplification occurred at a frequency of 4.8% (1,419 of 28,769 cases/patients) across all cancers and studies with gene amplification data ([Table 2](#pone.0199688.t002){ref-type="table"}). By combining the molecular data of studies from the same cancer subtype and site of origin, the most frequently *CCND1*-amplified cancer subtypes were head and neck squamous cell carcinoma (27.6%, 77 of 279 cases), breast cancer (16.7%, 735 of 4406 cases), bladder cancer (6.9%, 65 of 938 cases), esophageal-gastric cancer (4.8%, 72 of 1494 cases), non-small cell lung cancer (4.6%, 168 of 3648 cases), melanoma (3.3%, 23 of 708 cases), ovarian cancer (2.5%, 14 of 551 cases), appendiceal cancer (2.5%, 2 of 79 cases), hepatobiliary cancer (2.4%, 24 of 997 cases), prostate cancer (2.4%, 54 of 2262 cases) and endometrial cancer (2.3%, 11 of 480 cases).

10.1371/journal.pone.0199688.t002

###### Exome studies containing *CCND1* amplification with respective cancer type and *CCND1* amplification frequency.
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  Study   Cancer type (Source, citation)                     *CCND1* AMP   Sample size   \% amplified
  ------- -------------------------------------------------- ------------- ------------- --------------
  1       H&N Squamous Cell Carcinoma (TCGA, Nat 2015)       77            279           27.6%
  2       Meduloblastoma (Sickkids, Nature 2016)             52            213           24.4%
  3       Neuroendo Prostate Cancer (Tr/Corn/Broad 2016)     23            107           21.5%
  4       Breast Invasive Carcinoma (METABRIC, Nat 2012)     344           2051          16.8%
  5       Breast Invasive Carcinoma (TCGA, Cell 2015)        79            505           15.4%
  6       Bladder Cancer (MSKCC, J Clin Oncol 2013)          14            97            14.4%
  7       NCI-60 Cell Lines (NCI, Cancer Res. 2012)          8             60            13.3%
  8       Lung Squamous Cell Carcinoma (TCGA, Nat 2012)      22            178           12.4%
  9       Stomach/Esophageal (TCGA)                          32            265           12.1%
  10      Bladder Urothelial Carcinoma (TCGA, Nat 2014)      15            128           11.7%
  11      Cancer Cell Line Encyclop (Nov/Broad, Nat 2012)    112           995           11.3%
  12      Prostate Adenocarcinoma (Fred Hutchinson CRC)      14            136           10.3%
  13      Pancreatic Cancer (UTSW, Nat Commun 2015)          10            109           9.2%
  14      Bladder Cancer (MSKCC, Eur Urol 2014)              9             109           8.3%
  15      Non-small cell lung cancer (TCGA, 2016)            89            1144          7.8%
  16      Metastatic prostate carcinoma (Michig, Nat 2012)   4             61            6.6%
  17      Stomach Adenocarcinoma (TCGA, Nature 2014)         18            287           6.3%
  18      Liver HCC (AMC, Hepatology 2014)                   12            231           5.2%
  19      Breast cancer xenog (British Columbia, Nat 2014)   6             116           5.2%
  20      Metastatic Prostate, SU2C (Cell 2015)              7             150           4.7%
  21      Lung Adenocarcinoma (TCGA, Nature 2014)            10            230           4.3%
  22      MSK-IMPACT various tumor types (Nat Med 2017)      472           10945         4.3%
  23      Ovarian serous carcinoma (TCGA, Nature 2011)       19            489           3.9%
  24      Sarcoma (MSKCC/Broad, Nat Genet 2010)              7             207           3.4%
  25      Endometrial Carcinoma (TCGA, Nature 2013)          9             363           2.5%
  26      Prostate Adenocarcinoma (TCGA, Cell 2015)          7             333           2.1%
  27      Adenoid Cystic Carcinoma (MSKCC, Nat Gen 2013)     1             60            1.7%
  28      Lung Adenocarcinoma (Broad, Cell 2012)             3             182           1.6%
  29      Glioblastoma (TCGA, Cell 2013)                     3             563           0.5%
  30      Acute Myeloid Leukemia (TCGA, NEJM 2013)           1             191           0.5%
  31      LGG and GBM (TCGA, 2016)                           2             794           0.3%

*CCND1* mutations in primary endometrial adenocarcinomas {#sec010}
--------------------------------------------------------

Our analysis of *CCND1* mutations subsequently focused on two endometrial adenocarcinoma cohorts, since this cancer subtype was most frequently enriched for c-terminal cyclin D1 mutations ([Fig 1C and 1D](#pone.0199688.g001){ref-type="fig"}). First, we analyzed the primary endometrial adenocarcinoma (EMCA) cohort (n = 248) of the Cancer Genome Atlas Project (TCGA) study \[[@pone.0199688.ref018]\], in which *CCND1* was mutated in 6.1% (15 of 248) cases ([Table 1](#pone.0199688.t001){ref-type="table"}). In the TCGA EMCA cohort, the majority of *CCND1* mutations (60%, 9 of 15) were located in the carboxy terminal region of cyclin D1 ([Fig 1C](#pone.0199688.g001){ref-type="fig"} and [Table 3](#pone.0199688.t003){ref-type="table"}). Next, the pathological data was re-reviewed in terms of patient age, tumor type, stage and FIGO grade. Patient age in *CCND1*-mutated cases ranged from 33 to 76 years (Mean = 56; median = 58) ([Table 3](#pone.0199688.t003){ref-type="table"}). The majority of *CCND1*-mutated cases were of stage I (73%, 11 of 15) and FIGO grade 1 or 2 tumors (40% and 47% respectively) ([Table 3](#pone.0199688.t003){ref-type="table"}). A smaller percentage of *CCND1*-mutated primary TGCA EMCA tumors were stage III (20%, 3 of 15), stage IV (7%, 1 of 15) or FIGO grade 3 (13%, 2 of 15). For all *CCND1*-mutated TGCA EMCA cases, the tumors were of endometrioid histological subtype, which were confirmed by reviewing available H&E images ([Fig 2](#pone.0199688.g002){ref-type="fig"}).

![H&E images of representative endometrial endometrioid adenocarcinoma cases containing activating *CCND1* T286I and P287S mutations.\
A (40x, case D1-A0ZO), B (400x, case D1-A0ZO) and C (40x, case B5-A0JV): grade 1 endometrioid adenocarcinoma containing T286I mutations. D (40x, case D1-A0ZU): grade 1 endometrioid adenocarcinoma containing P287S mutation. E (40x, case D1-A17D) and F (400x, case D1-A17D): grade 3 endometrioid adenocarcinoma containing P287S mutation.](pone.0199688.g002){#pone.0199688.g002}

10.1371/journal.pone.0199688.t003

###### *CCND1* mutations in primary endometrial adenocarcinomas of the TCGA cohort (n = 248) with corresponding patient clinico-pathological characteristics.

![](pone.0199688.t003){#pone.0199688.t003g}

  n    Sample ID   Mutation                                    Type       Effect             Age   Histologic Type   Grade   Stage
  ---- ----------- ------------------------------------------- ---------- ------------------ ----- ----------------- ------- -------
  1    AP-A0LM     E135D                                       Missense   Unknown            33    Endometrioid      2       III
  2    AX-A0J0     A171V                                       Missense   Unknown            47    Endometrioid      2       I
  3    AX-A05Z     F232L                                       Missense   Unknown            37    Endometrioid      1       III
  4    AX-A063     D240N                                       Missense   Unknown            63    Endometrioid      2       I
  5    AP-A054     C243R                                       Missense   Unknown            64    Endometrioid      2       III
  6    BG-A0MQ     L244I                                       Missense   Unknown            71    Endometrioid      1       I
  7    AX-A062     E275[\*](#t003fn002){ref-type="table-fn"}   Nonsense   Likely oncogenic   53    Endometrioid      2       I
  8    BS-A0TA     E280del                                     IF del     Unknown            58    Endometrioid      2       IV
  9    B5-A0JV     T286I                                       Missense   Oncogenic          63    Endometrioid      1       I
  10   D1-A0ZO     T286I                                       Missense   Oncogenic          75    Endometrioid      1       I
  11   D1-A0ZU     P287S                                       Missense   Oncogenic          34    Endometrioid      2       I
  12   D1-A17D     P287S                                       Missense   Oncogenic          58    Endometrioid      3       I
  13   BS-A0TJ     R291dup                                     IF ins     Likely oncogenic   59    Endometrioid      3       I
  14   D1-A16D     R291_V293                                   IF del     Likely oncogenic   49    Endometrioid      1       I
  15   BS-A0U5     V293G                                       Missense   Unknown            76    Endometrioid      1       I

IF del = in frame deletion; FS Ins = frame shift insertion

\* = truncating mutations.

The TCGA has previously stratified endometrioid endometrial adenocarcinomas into 4 different molecular subgroups: 1) low copy-number alterations, 2) high copy-number alterations (serous-like), 3) POLE ultramutated and 4) microsatellite instability hypermutated \[[@pone.0199688.ref018]\]. Within this molecular stratification system, we identified c-terminal cyclin D1 mutations in the low copy-number alterations and in the microsatellite instability hypermutated molecular subgroups (data not shown), both of which have intermediate prognosis. In contrast, no c-terminal cyclin D1 mutations were identified in the POLE ultramutated (best prognosis) and in the copy-number high, serous-like (worst prognosis) molecular subgroups (data not shown) or in TCGA tumors with specific serous-type histology (data not shown).

*CCND1* mutations in advanced or metastatic endometrial carcinoma {#sec011}
-----------------------------------------------------------------

We next interrogated the endometrial carcinoma cohort of cases from the MSK-IMPACT study in order to determine whether *CCND1* c-terminal mutations also occurred in the advanced or metastatic endometrial carcinoma setting \[[@pone.0199688.ref019]\]. In this cohort of advanced EMCA (n = 210), *CCND1* was mutated in 7% (15 of 210) cases with the majority of mutations (80%, 12 of 15) located in the c-terminus of cyclin D1 ([Fig 1D](#pone.0199688.g001){ref-type="fig"} and [Table 4](#pone.0199688.t004){ref-type="table"}). Of the 15 total *CCND1*-mutated cases identified, molecular data was available in 10 metastatic sites, in which the c-terminus of *CCND1* was mutated in 80% (8 of 10) metastatic EMCA sites. While H&E images were not available for re-review, the majority of *CCND1*-mutated MSK-IMPACT advanced or metastatic EMCA cases were reportedly of endometrioid histological subtype (86.7%, 13 of 15). Additionally, one reportedly undifferentiated endometrial carcinoma also contained a c-terminal *CCND1* mutation, while an endometrial serous carcinoma contained an n-terminal cyclin D1 mutation of unknown functional significance ([Table 4](#pone.0199688.t004){ref-type="table"}). The combined overall findings of both TCGA and MSK-IMPACT EMCA cohorts support the notion that *CCND1* c-terminal mutations are enriched in endometrial endometrioid-type carcinomas in both primary and advanced metastatic settings.

10.1371/journal.pone.0199688.t004

###### *CCND1* mutations in advanced or metastatic endometrial carcinomas of the MSK-IMPACT cohort (n = 15) with corresponding patient clinico-pathological characteristics and *CCND1* mutation effect.
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  n    Sample ID      Mutation                                         Type       Effect             Histologic Type    Site             Status
  ---- -------------- ------------------------------------------------ ---------- ------------------ ------------------ ---------------- ----------
  1    P0008646-T01   T12I                                             Missense   Unknown            Endometrioid       Abdominal met    Deceased
  2    P0000230-T01   N24S                                             Missense   Unknown            Serous             Primary uterus   Living
  3    P0012358-T01   S55F                                             Missense   Unknown            Endometrioid       Vaginal met      Living
  4    P0012397-T01   A171V                                            Missense   Unknown            Endometrioid       Primary uterus   Living
  5    P0012058-T01   E275[\*](#t004fn002){ref-type="table-fn"}        Nonsense   Likely oncogenic   Endometrioid       Primary uterus   Living
  6    P0000069-T01   E279[\*](#t004fn002){ref-type="table-fn"}        Nonsense   Likely oncogenic   Endometrioid       Colonic met      Living
  7    P0012152-T01   L283_D294del                                     IF del     Oncogenic          Endometrioid       Peritoneal met   Living
  8    P0001248-T01   T286I                                            Missense   Oncogenic          Endometrioid       Lymph node met   Living
  9    P0006849-T01   T286I                                            Missense   Oncogenic          Undifferentiated   Primary uterus   Living
  10   P0009518-T01   T286I                                            Missense   Oncogenic          Endometrioid       Muscle met       Living
  11   P0010310-T01   T286I                                            Missense   Oncogenic          Endometrioid       Primary uterus   Deceased
  12   P0003767-T01   P287A                                            Missense   Oncogenic          Endometrioid       Omental met      Living
  13   P0011569-T01   P287S                                            Missense   Oncogenic          Endometrioid       Primary uterus   Living
  14   P0005285-T01   D289del                                          IF del     Oncogenic          Endometrioid       Pelvic met       Deceased
  15   P0005285-T02   D289del                                          IF del     Oncogenic          Endometrioid       Primary uterus   Deceased
  16   P0008444-T01   V290Afs[\*](#t004fn002){ref-type="table-fn"}66   FS Ins     Likely oncogenic   Endometrioid       Lung met         Deceased
  17   P0008646-T01   V293del                                          IF del     Likely oncogenic   Endometrioid       Abdominal met    Deceased

Note: one tumor (P0008646-T01) had more than 1 *CCND1* mutation, and one patient (P0005285) had two samples analyzed (primary and metastatic tumors). IF del = in frame deletion; FS Ins = frame shift insertion

\* = truncating mutations.

Functional effect of c-terminal *CCND1* mutations in endometrial cancer {#sec012}
-----------------------------------------------------------------------

The majority of *CCND1*-mutated endometrial cancer cases (70%, 21 of 30 endometrial cancers, Tables [3](#pone.0199688.t003){ref-type="table"} and [4](#pone.0199688.t004){ref-type="table"}) contained mutations in the c-terminus of cyclin D1 that may be implicated in cyclin D1 activation and gain-of-function (Tables [3](#pone.0199688.t003){ref-type="table"} and [4](#pone.0199688.t004){ref-type="table"}). Recurrent activating mutations in endometrial cancer included: E275\*, T286I (most common), P287S (second most common), D289del ([Fig 1C and 1D](#pone.0199688.g001){ref-type="fig"} and Tables [3](#pone.0199688.t003){ref-type="table"} and [4](#pone.0199688.t004){ref-type="table"}). Less frequent mutations in endometrial cancer that are also likely oncogenic included: E279\*, L283_294del, V290Afs\*, R291dup, R291_V293del and V293del (Tables [3](#pone.0199688.t003){ref-type="table"} and [4](#pone.0199688.t004){ref-type="table"}). Based on prior *in vitro* and *in vivo* studies, these mutations are predicted to drive cellular transformation and activation of CDK4/6 by disrupting cyclin D1 Thr-286 phosphorylation, nuclear export and proteasome-mediated degradation \[[@pone.0199688.ref012]\]\[[@pone.0199688.ref010]\]\[[@pone.0199688.ref011]\]. These findings suggest that a subset endometrial adenocarcinomas possesses a unique spectrum of somatic *CCND1* mutations in which activating mutations occurring in the carboxy terminal domain of cyclin D1 are enriched, compared to other cancer types, thereby promoting cyclin D1 nuclear expression, gain of function and oncogenic activation.

Co-occurring mutations in endometrial cancer {#sec013}
--------------------------------------------

TCGA cases exhibiting C-terminal *CCND1* mutations had frequent co-occurring mutations of genes implicated in the pathogenesis of endometrial endometrioid adenocarcinomas, as the majority of *CCND1*-mutated cases exhibited mutations of *ARID1A* and members of the PI3K signaling pathway, *PTEN* and *PIK3CA*. Less frequent co-occurring mutations were seen in other genes involved in endometrial carcinogenesis such as *KRAS*, *CTNNB1*, *ARID5B* and *PMS2* in a minority of *CCND1*-mutated cases. In contrast, there were no co-occurring mutations of *TP53*, which is frequently mutated in endometrial serous and serous-like carcinomas, or of *POLE*, which is altered in ultramutated endometrial carcinomas, or of *MSH2*, *MSH6* and *MLH1*, which are mutated in microsatellite unstable endometrial carcinomas ([S2 Fig](#pone.0199688.s004){ref-type="supplementary-material"}).

C-terminal *CCND1* mutations in other cancer types {#sec014}
--------------------------------------------------

Although occurring less frequently than in endometrial cancer, c-terminal activating *CCND1* mutations were also identified in other cancer types, such as gastrointestinal adenocarcinoma (esophageal, stomach, colorectal, ampula of vater), squamous cell carcinoma (head & neck, lung, skin), urothelial carcinoma, cutaneous melanoma, angiosarcoma, ovarian carcinoma (low grade serous and endometrioid types) and uterine epithelioid leiomyosarcoma ([Table 5](#pone.0199688.t005){ref-type="table"}). The most common activating mutations occurred in amino acids P287 and T286 as missense mutations, or as nonsense mutations in amino acids Q261, E275, E279, E280, E285, all of which are predicted to directly disrupt the phospho-degron site and/or nuclear export signal of cyclin D1, thereby resulting in nuclear accumulation and protein overexpression. The rate of overall and c-terminal activating *CCND1* mutations in these non-endometrial carcinoma types was rare, at most approximately 1% in melanoma and colorectal carcinoma. The overall rate of *CCND1* mutations was 1.1% in colorectal carcinoma and cutaneous melanoma (23 of 2,067 cases and 8 of 708 cases respectively) with a smaller percentage of mutations occurring specifically in the c-terminal region of cyclin D1 (0.7%, 5 of 708 cases in cutaneous melanoma and 0.4%, 9 of 2067 in colorectal carcinoma).

10.1371/journal.pone.0199688.t005

###### C-terminal *CCND1* mutations across other non-endometrial carcinoma and non-mantle cell lymphoma cancer types.

![](pone.0199688.t005){#pone.0199688.t005g}

  Study                                             Sample ID           Cancer Type               Mutation                                    Effect             Type
  ------------------------------------------------- ------------------- ------------------------- ------------------------------------------- ------------------ ----------
  Ampullary Carcinoma (Baylor, Cell Rep 2016)       DUOAC_781           Ampulla of Vater          Q261[\*](#t005fn002){ref-type="table-fn"}   Likely oncogenic   Nonsense
  MSK-IMPACT (MSKCC, Nat Med 2017)                  P-0000148-T01-IM3   LG serous ovarian CA      Q261[\*](#t005fn002){ref-type="table-fn"}   Likely oncogenic   Nonsense
  MSK-IMPACT (MSKCC, Nat Med 2017)                  P-0003765-T01-IM5   Angiosarcoma              Q264[\*](#t005fn002){ref-type="table-fn"}   Likely oncogenic   Nonsense
  Melanoma (Broad/Dana Farber, Nature 2012)         ME049               Melanoma                  A270T                                       Unknown            Missense
  Pan-Lung Cancer (TCGA, Nat Genet 2016)            TCGA-44-3396-01     Lung Adenocarcinoma       A271S                                       Unknown            Missense
  Esophagus-Stomach Cancers (TCGA, Nat 2017)        TCGA-BR-4363-01     Stomach ACA               A271T                                       Unknown            Missense
  Pan-Lung Cancer (TCGA, Nat Genet 2016)            TCGA-51-6867-01     Lung SCC                  E275[\*](#t005fn002){ref-type="table-fn"}   Likely oncogenic   Nonsense
  MSK-IMPACT (MSKCC, Nat Med 2017)                  P-0012241-T02-IM5   Lung SCC                  E276V                                       Unknown            Missense
  Colorectal ACA (DFCI, Cell Reports 2016)          dfci_2016_3091      Colorectal ACA            E278G                                       Unknown            Missense
  MSK-IMPACT (MSKCC, Nat Med 2017)                  P-0004495-T01-IM5   Lung SCC                  E279[\*](#t005fn002){ref-type="table-fn"}   Likely oncogenic   Nonsense
  Bladder Urothelial Carcinoma (TCGA, Nat 2014)     TCGA-DK-A1A6-01     Bladder urothelial CA     E280del                                     Unknown            IF_Del
  Esophagus-Stomach Cancers (TCGA, Nat 2017)        TCGA-KH-A6WC-01     Esophageal SCC            E280del                                     Unknown            IF_Del
  Melanoma tumors (UCLA, Cell 2016)                 Pt11                Cutaneous melanoma        E280[\*](#t005fn002){ref-type="table-fn"}   Likely oncogenic   Nonsense
  Colorectal ACA (DFCI, Cell Reports 2016)          dfci_2016_3064      Colorectal ACA            E280V                                       Unknown            Missense
  H&N SCC (TCGA, Nature 2015)                       TCGA-CV-6441-01     Head &Neck SCC            D282H                                       Unknown            Missense
  Colorectal ACA (DFCI, Cell Reports 2016)          dfci_2016_111       Colorectal ACA            A284V                                       Unknown            Missense
  Esophagus-Stomach Cancers (TCGA, Nat 2017)        TCGA-L5-A8NM-01     Esophageal ACA            C285[\*](#t005fn002){ref-type="table-fn"}   Likely oncogenic   Nonsense
  H&N SCC (TCGA, Nature 2015)                       TCGA-CV-6441-01     Head & Neck SCC           C285_P287del                                Likely oncogenic   IF_Del
  MSK-IMPACT (MSKCC, Nat Med 2017)                  P-0011446-T01-IM5   Colorectal ACA            T286A                                       Oncogenic          Missense
  Colorectal ACA (DFCI, Cell Reports 2016)          dfci_2016_2624      Colorectal ACA            T286I                                       Oncogenic          Missense
  Colorectal ACA (DFCI, Cell Reports 2016)          dfci_2016_3319      Colorectal ACA            T286I                                       Oncogenic          Missense
  MSK-IMPACT (MSKCC, Nat Med 2017)                  P-0005364-T01-IM5   Up. tract urothelial CA   T286I                                       Oncogenic          Missense
  Pan-Lung Cancer (TCGA, Nat Genet 2016)            TCGA-85-8072-01     Lung SCC                  P287A                                       Oncogenic          Missense
  Melanoma (Broad/Dana Farber, Nature 2012)         ME024               Melanoma                  P287L                                       Oncogenic          Missense
  MSK-IMPACT (MSKCC, Nat Med 2017)                  P-0000396-T01-IM3   Oropharynx SCC            P287L                                       Oncogenic          Missense
  Skin SCC (DFCI, Clin Cancer Res 2015)             TP-S07-16280-NT     Cutaneous SCC             P287L                                       Oncogenic          Missense
  Cancer Cell Line Encyclopedia (Broad, Nat 2012)   OVK18_OVARY         Ovary endometrioid CA     P287R                                       Oncogenic          Missense
  MSK-IMPACT (MSKCC, Nat Med 2017)                  P-0001821-T01-IM3   Uterine epithelioid LMS   P287S                                       Oncogenic          Missense
  MSK-IMPACT (MSKCC, Nat Med 2017)                  P-0005455-T01-IM5   Colon ACA                 P287S                                       Oncogenic          Missense
  Colorectal ACA (DFCI, Cell Reports 2016)          dfci_2016_2564      Colorectal ACA            R291W                                       Unknown            Missense
  MSK-IMPACT (MSKCC, Nat Med 2017)                  P-0001685-T01-IM3   Rectal ACA                D292G                                       Unknown            Missense

Note: IF_del = in frame deletion

\* = truncating mutations.

CA = carcinoma; ACA = adenocarcinoma; SCC = squamous cell carcinoma; LMS = leiomyosarcoma.

Discussion {#sec015}
==========

Cyclin D1, encoded by the *CCND1* gene, is a core cell cycle protein that promotes cellular proliferation by activating CDK4/6 kinases and progression of the G1-S phase of cell cycle. *CCND1* acts as oncogene and is frequently overexpressed in a variety of cancers often via gene amplification or gene rearrangement \[[@pone.0199688.ref023]\]\[[@pone.0199688.ref024]\]\[[@pone.0199688.ref025]\]. Recently, *CCND1* mutations inhibiting Thr286 phosphorylation, nuclear export and ubiquitin-mediated degradation by the proteasome have been shown to result in constitutive activation of CDK4/6 complexes, thereby promoting cellular proliferation and malignant transformation both *in vitro* and *in vivo* \[[@pone.0199688.ref006]\]\[[@pone.0199688.ref007]\]\[[@pone.0199688.ref008]\]. Corroborating its oncogenic potential, *CCND1* mutations affecting Thr286 phosphorylation and inhibiting nuclear export have been reported in a few cancers \[[@pone.0199688.ref010]\]\[[@pone.0199688.ref012]\]\[[@pone.0199688.ref011]\]; however, the frequency and spectrum of *CCND1* mutations have not been systematically investigated or reported across a large series of cases and across a variety of cancer subtypes. We exploited and mined the publicly available data of the Cancer Genome Atlas Project and other published exome sequencing studies to interrogate the frequency, spectrum and oncogenic effects of *CCND1* mutations across of a large number and diverse set of human cancers.

Here, we demonstrate that *CCND1* mutations are of very low frequency across the vast majority of cancer types (0.5%, 151 of 29,432 cases), but are predominantly enriched in endometrial endometrioid carcinomas in both the primary and metastatic settings (6.5%, 30 of 458 cases). In endometrial cancer, the majority of *CCND*1 mutations were located in the carboxy-terminal region of cyclin D1 (70%, 21 of 30 endometrial cancers), likely resulting in cyclin D1 oncogenic activation of cyclin D1-CDK4/6 complexes and gain of function. To our knowledge, this is the first study to systematically evaluate and report activating c-terminal *CCND1* mutations across a large number of diverse cancer types. Our results are in line with two other previously published studies in which oncogenic, c-terminal cyclin D1 mutations were identified in endometrial cancer \[[@pone.0199688.ref010]\]\[[@pone.0199688.ref011]\]. Ikeda et al identified *CCND1* mutations in 2.3% (2 of 88) of endometrial cancer cases. Their two reported mutated cases contained a T286I mutation, which resulted in constitutive cyclin D1 nuclear accumulation and oncogenic activation \[[@pone.0199688.ref011]\]. Likewise, in an independent endometrial cancer cohort, Moreno-Bueno et al identified *CCND1* mutations in 2.5% (3 of 119) endometrial cancer cases. Two cases demonstrated mutation at amino acid P287 (P287S and P287T), while a third case contained a 12-bp in-frame deletion that eliminated amino acids 289--292, all of which resulted in cyclin D1 nuclear expression in more than 50% of endometrial cancer cells \[[@pone.0199688.ref010]\]. Importantly, Benzeno et al independently confirmed that *CCND1* mutations at T286, P287, D289 or deletion of amino acids 289--292 resulted in cyclin D1 nuclear retention, activation of CDK4/6 kinase and cellular transformation \[[@pone.0199688.ref012]\]. The rate of overall *CCND1* mutations in endometrial cancer in our study is higher than that reported by Ikeda et al and Moreno-Bueno et al, likely reflecting the fact that the two prior studies sequenced a target region of cyclin D1 as opposed to next generation sequencing of the whole *CCND1* gene. Our study expands the findings of Moreno-Bueno et al and Ikeda et al \[[@pone.0199688.ref010]\]\[[@pone.0199688.ref011]\], in which *CCND1* mutations at amino acids T286, P287, D289, deletion of amino acids 289--292 and potentially other c-terminal CCND1 mutations, such as nonsense mutation at E275\*, E279\*, may be important in the pathogenesis of a subset of endometrial cancers.

Importantly, the majority of TCGA cases exhibiting c-terminal *CCND1* mutations had frequent co-occurring mutations of *ARID1A* and members of the PI3K signaling pathway, *PTEN* and *PIK3CA*, suggesting that alterations these molecular pathways are also required in addition to oncogenic nuclear cyclin D1 activation in a subset of endometrial cancers. In addition, a search of the BROAD Institute gene variant database--derived from whole exomes of healthy individuals from many ethnic or geographic settings did not reveal any of the oncogenic c-terminal *CCND1* mutations or polymorphisms indentified in our study in a control population that did not harbor cancer.

Our results also corroborate the findings of Chang et al, who identified Proline 287 as a recurrent hotspot mutated amino acid of cyclin D1 in a population-scale cohort of tumor samples of various cancer types \[[@pone.0199688.ref026]\]. Consistent with the findings of Chang et al, Proline 287 was the most commonly mutated amino acid of cyclin D1 across all cancer types in our study. We identified mutations in cyclin D1 at Proline 287 in a diverse tumor set including melanoma, endometrial carcinoma, colonic adenocarcinoma, ovarian endometrioid adenocarcinoma, uterine leyomyosarcoma and squamous cell carcinoma of lung, oro-pharynx and skin, thus supporting the notion that *CCND1* driver mutations at Pro287 may be a recurrent hotspot in cancer.

In addition, we also demonstrate high frequency of oncogenic *CCND1* mutations at or surrounding amino acid Threonine 286 in the c-terminus and at or surrounding Tyrosine 44 at the n-terminus, albeit in different tumor types (i.e. carcinoma, particularly endometrial, and mantle cell lymphoma respectively). Of note, in mantle cell lymphoma, it has also been previously demonstrated that, compared to wild type *CCND1*, n-terminal E36K, Y44D or C47S *CCND1* mutations are likely oncogenic and increased cyclin D1 protein levels through attenuation of threonine-286 phosphorylation, thereby promoting resistance to ibrutinib, which is an FDA-approved Bruton tyrosine kinase inhibitor for mantle cell lymphoma treatment \[[@pone.0199688.ref027]\]. Future studies are needed in order to determine whether patients, whose tumors contain oncogenic activating mutations of *CCND1*, would benefit from precision medicine by targeting cyclin D1-CDK4/6 kinase complexes with specific inhibitors.

In the past decade, the genomic landscape of many different types of tumors have been studied and deposited in publicly available data portals \[[@pone.0199688.ref028]\]. In addition, the clinical sequencing of advanced, metastatic tumors is becoming a mainstay in cancer care to guide potential treatment in mutation- and target-specific precision medicine \[[@pone.0199688.ref019]\]. In both clinical and preclinical research settings, a host of tools and resources can be used to interrogate specific genetic events relative to clinico-pathological characteristics of patient tumors as well as to generate hypotheses for future testing. Currently, the treatment options for advanced endometrial cancer patients are limited, and there is scant data with regards to the efficacy of palbociclib, a CDK4/6 specific inhibitor, towards endometrial cancer. In preclinical models, palbociclib or knockout of cyclin D1 had therapeutic potential against endometrial cancer cell lines and xenografts expressing the retinoblastoma protein, Rb \[[@pone.0199688.ref029]\]\[[@pone.0199688.ref030]\]. Lastly, our findings implicate oncogenic c-terminal mutations of *CCND1* in the pathogenesis of a subset of human cancers and provide a key resource to guide future preclinical and clinical investigations, especially with regards to the use of palbociclib or similar CDK4/6 specific inhibitors in a subset of endometrial cancers.
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###### *CCND1* mutations in the mantle cell lymphoma IBIDIPS cohort.

IF del = in frame deletion; FS Ins = frame shift insertion; \* = truncating mutations.
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Diagrams of *CCND1* mutations in multiple myeloma (A), in colorectal adenocarcinoma (B) and in cutaneous melanoma (C).
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###### Diagram of co-occurring mutations of genes frequently implicated in endometrial cancer in the TCGA cohort of endometrial carcinoma cases exhibiting *CCND1* mutations.

Square denotes presence of gene mutation. Red bar denotes presence of c-terminal *CCND1* mutation.
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